The FDA has placed a clinical hold on the phase 1/2 study of Vertex Pharmaceuticals’ investigational stem cell-derived therapy for type 1 diabetes.
Source: Drug Industry Daily
The FDA has placed a clinical hold on the phase 1/2 study of Vertex Pharmaceuticals’ investigational stem cell-derived therapy for type 1 diabetes.
Source: Drug Industry Daily